Cianna Medical Inc.
This article was originally published in Start Up
Executive Summary
Women diagnosed with early-stage breast cancer are increasingly choosing breast conservation therapy - lumpectomy followed by several weeks of daily whole breast irradiation - over mastectomy. But because the vast majority of cancer recurs at or near the lumpectomy cavity, there has been a shift toward more localized radiation. The Strut-Adjusted Volume Implant from Cianna Medical Inc. is a form of accelerated partial breast irradiation that combines tissue-sparing dosimetry with a single-entry device. Once inserted, the multi-catheter device expands to reveal numerous treatment pathways.
You may also be interested in...
The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
Start-Up Previews
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”